1.24
-69.68%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zura Bio
From its filings with the US Securities and Exchange Commission
Zura Bio is based in La Jolla, California and is incorporated in Cayman Islands. Its shares trade on Nasdaq under the ticker ZURA. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported a net loss of $68.7m. At that date it held total assets of $113.9m and shareholders' equity of $101.5m.
We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with significant unmet medical need. These diseases are often chronic, biologically complex and difficult to treat, and many patients do not achieve durable disease control with currently available therapies.
Our strategy is to identify immune-mediated diseases in which translational and clinical evidence supports the role of specific biological pathways in disease pathogenesis. We focus on targets for which human data, including biomarker findings, genetic associations and prior clinical studies, inform therapeutic rationale and development decisions. We seek to advance product candidates in therapeutic areas where there remains meaningful unmet medical need and where, if clinical benefit is demonstrated, there may be potential for commercial relevance.
1.Tibulizumab (ZB-106), a humanized bispecific antibody engineered to bind and neutralize interleukin-17A (“IL-17A”) and B cell activating factor (“BAFF”) within a single therapeutic molecule.
Quoted from its 10-K, filed 19 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Jul 2021
- Employees
- 40
- Website
- zurabio.com ↗
- Head office
- 4225 EXECUTIVE SQUARE, LA JOLLA, CA, 92037
- Incorporated in
- E9
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Amit MunshiIndependent Chairman of the Board$338,207
- Mr. Robert LisickiChief Executive Officer, Director, since 2024$6.7m
- Mr. Verender BadialChief Financial Officer, since 2023$3.5m
- Mr. Eric HyllengrenChief Financial Officer
- Ms. Kim DavisChief Operating Officer, Chief Legal Officer and Corporate Secretary$1.8m
- Mr. Gary WhaleChief Technology Officer
- Dr. Kiran NistalaChief Medical Officer, Head of Development$2.5m
- Dr. Someit SidhuDirector, since 2024$1.0m
- Dr. Dan BeckerIndependent Director
- Dr. Neil GrahamIndependent Director$305,207
- Ms. Jennifer JarrettIndependent Director$307,207
- Mr. Sandeep KulkarniIndependent Director$317,207
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 19
- Environment
- 24
- Social
- 2
- Governance
- 32
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zura Bio is a clinical-stage biotechnology company focused on immune disorders.
- The firm is advancing assets like ZB-168 and torudokimab into phase II development.
- ZB-168 has demonstrated a safety profile and biological rationale in type 1 diabetes.
Weaknesses
- The company has a small workforce of only 40 employees.
- Zura Bio went public in 2021 and remains in the clinical development stage.
- The firm is headquartered in La Jolla, California, within the US market.
Opportunities
- The company can develop a portfolio of therapeutic indications for ZB-168.
- ZB-168 targets diseases driven by interleukin-7 and TSLP biological pathways.
- Torudokimab is a high affinity monoclonal antibody neutralizing interleukin-33.
Threats
- The source description is treated as untrusted facts for this analysis.
- Biotechnology development carries inherent risks during phase II clinical trials.
- Market conditions for clinical-stage companies can be volatile and uncertain.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.